cells

Hepion Pharmaceuticals

US: HEPA

Market Cap$114m

Last Close $1.5

Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for chronic liver disease. The company’s lead asset is CRV431, a cyclophilin inhibitor being developed for the treatment of non-alcoholic steatohepatitis (NASH).

More Hepion Pharmaceuticals content >

Investment summary

Recently, Hepion released top-line data from its AMBITION Phase IIa trial with CRV431, a cyclophilins inhibitor, in non-alcoholic steatohepatitis (NASH) patients. All primary safety, tolerability and pharmacokinetics were met and support once-a-day dosing. The company plans to conduct a Phase IIb (ASCEND-NASH) trial this year in NASH patients with fibrosis levels 2 or 3 (F2 or F3). The ASCEND-NASH trial will be significantly larger with 300 patients enrolled. The primary endpoint will be a 1-point reduction in fibrosis score in liver biopsies.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2019A 0.0 (7.7) (7.9) (341.55) N/A N/A
2020A 0.0 (17.7) (17.9) (185.69) N/A N/A
2021E 0.0 (27.0) (27.0) (35.49) N/A N/A
2022E 0.0 (28.5) (28.5) (35.68) N/A N/A
Content on Hepion Pharmaceuticals
Hepion Pharmaceuticals – Phase IIa readout upcoming
Healthcare | Update | 7 April 2021
cells
View more
Register to receive research on Hepion Pharmaceuticals as it is published
Share price graph
Balance sheet
Forecast net cash (US$m) 102.2
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 4.9 (28.9) (53.8)
Relative* 7.0 (31.0) (65.2)
52-week high/low US$3.6/US$1.4
*% relative to local index
Key management
Robert Foster CEO
John Cavan FD